Literature DB >> 18506476

TRESK-like potassium channels in leukemic T cells.

Igor I Pottosin1, Edgar Bonales-Alatorre, Georgina Valencia-Cruz, Maria Luisa Mendoza-Magaña, Oxana R Dobrovinskaya.   

Abstract

In this study, we present patch-clamp characterization of the background potassium current in human lymphoma (Jurkat cells), generated by voltage-independent 16 pS channels with a high ( approximately 100-fold) K+/Na+ selectivity. Depending on the background K+ channels density, from few per cell up to approximately 1 open channel per microm2, resting membrane potential was in the range of -40 to -83 mV, approaching E (K) = -88 mV. The background K+ channels were insensitive to margotoxin (3 nM), apamine (3 nM), and clotrimazole (1 microM), high-affinity blockers of the lymphocyte Kv1.3, SKCa2, and IKCa1 channels. The current depended weakly on external pH. Arachidonic acid (20 microM) and Hg2+ (0.3-10 microM) suppressed background K+ current in Jurkat cells by 75-90%. Background K+ current was weakly sensitive to TEA+ (IC50 = 14 mM), and was efficiently suppressed by externally applied bupivacaine (IC50 = 5 microM), quinine (IC50 = 16 microM), and Ba2+ (2 mM). Our data, in particular strong inhibition by mercuric ions, suggest that background K+ currents expressed in Jurkat cells are mediated by TWIK-related spinal cord K+ (TRESK) channels belonging to the double-pore domain K+ channel family. The presence of human TRESK in the membrane protein fraction was confirmed by Western blot analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506476     DOI: 10.1007/s00424-008-0481-x

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  42 in total

1.  Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels.

Authors:  C M Fanger; H Rauer; A L Neben; M J Miller; H Rauer; H Wulff; J C Rosa; C R Ganellin; K G Chandy; M D Cahalan
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

2.  Potent activation of the human tandem pore domain K channel TRESK with clinical concentrations of volatile anesthetics.

Authors:  Canhui Liu; John D Au; Hilary Liao Zou; Joseph F Cotten; C Spencer Yost
Journal:  Anesth Analg       Date:  2004-12       Impact factor: 5.108

3.  Pig paramyxovirus of the blue eye disease binding to a 116 kDa glycoprotein expressed in pig neuronal membranes.

Authors:  M L Mendoza-Magaña; M A Ramírez-Herrera; J M Dueñas-Jiménez; S H Dueñas-Jiménez
Journal:  J Vet Med B Infect Dis Vet Public Health       Date:  2001-09

4.  A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes.

Authors:  N J Logsdon; J Kang; J A Togo; E P Christian; J Aiyar
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

5.  Targeting of calcineurin to an NFAT-like docking site is required for the calcium-dependent activation of the background K+ channel, TRESK.

Authors:  Gábor Czirják; Péter Enyedi
Journal:  J Biol Chem       Date:  2006-03-28       Impact factor: 5.157

6.  A voltage-gated potassium channel in human T lymphocytes.

Authors:  M D Cahalan; K G Chandy; T E DeCoursey; S Gupta
Journal:  J Physiol       Date:  1985-01       Impact factor: 5.182

7.  Zinc and mercuric ions distinguish TRESK from the other two-pore-domain K+ channels.

Authors:  Gábor Czirják; Péter Enyedi
Journal:  Mol Pharmacol       Date:  2005-12-14       Impact factor: 4.436

8.  Differential effects of mercury, lead, and cadmium on IL-2 production by Jurkat T cells.

Authors:  Myrian Colombo; Claudine Hamelin; Edouard Kouassi; Michel Fournier; Jacques Bernier
Journal:  Clin Immunol       Date:  2004-06       Impact factor: 3.969

9.  Quinidine-induced open channel block of K+ current in rat ventricle.

Authors:  R B Clark; J Sanchez-Chapula; E Salinas-Stefanon; H J Duff; W R Giles
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

10.  Ca(2+)-activated K+ channels in human leukemic T cells.

Authors:  S Grissmer; R S Lewis; M D Cahalan
Journal:  J Gen Physiol       Date:  1992-01       Impact factor: 4.086

View more
  8 in total

Review 1.  Properties, regulation, pharmacology, and functions of the K₂p channel, TRESK.

Authors:  Péter Enyedi; Gábor Czirják
Journal:  Pflugers Arch       Date:  2014-11-05       Impact factor: 3.657

2.  TRESK background K(+) channel is inhibited by phosphorylation via two distinct pathways.

Authors:  Gábor Czirják; Péter Enyedi
Journal:  J Biol Chem       Date:  2010-03-09       Impact factor: 5.157

Review 3.  Molecular basis of calcium signaling in lymphocytes: STIM and ORAI.

Authors:  Patrick G Hogan; Richard S Lewis; Anjana Rao
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 4.  The CNS under pathophysiologic attack--examining the role of K₂p channels.

Authors:  Petra Ehling; Manuela Cerina; Thomas Budde; Sven G Meuth; Stefan Bittner
Journal:  Pflugers Arch       Date:  2014-12-09       Impact factor: 3.657

Review 5.  The functional network of ion channels in T lymphocytes.

Authors:  Michael D Cahalan; K George Chandy
Journal:  Immunol Rev       Date:  2009-09       Impact factor: 12.988

Review 6.  Placing ion channels into a signaling network of T cells: from maturing thymocytes to healthy T lymphocytes or leukemic T lymphoblasts.

Authors:  Oxana Dobrovinskaya; Iván Delgado-Enciso; Laura Johanna Quintero-Castro; Carlos Best-Aguilera; Rocío Monserrat Rojas-Sotelo; Igor Pottosin
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

7.  Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Authors:  Oxana Dobrovinskaya; Georgina Valencia-Cruz; Luis Castro-Sánchez; Edgar O Bonales-Alatorre; Liliana Liñan-Rico; Igor Pottosin
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

8.  Tubulin binds to the cytoplasmic loop of TRESK background K⁺ channel in vitro.

Authors:  Péter Enyedi; Irén Veres; Gabriella Braun; Gábor Czirják
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.